BioNexus Gene Lab Corp - Common stock (NQ:BGLC)

2.320 -0.080 (-3.33%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 29, 2026 Add to My Watchlist

Price and Volume

Volume	213,524
Open	2.400
Bid (Size)	2.280 (3,300)
Ask (Size)	2.400 (400)
Prev. Close	2.400
Today's Range	2.080 - 2.400
52wk Range	1.920 - 15.60
Shares Outstanding	1,796,507
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

BioNexus Gene Lab Corp. Calls for Malaysia–China Biotechnology Cooperation to Move Beyond Trade into Co-Development

Today 9:00 EDT

From BioNexus Gene Lab Corp.

Via GlobeNewswire

BioNexus Gene Lab Corp. Announces Appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to Lead Global Commercialization of the VitaGuard™ MRD Platform

March 11, 2026

From BioNexus Gene Lab Corp.

Via GlobeNewswire

Performance

YTD	-41.1%	-41.1%
1 Month	+12.1%	+12.1%
3 Month	-7.2%	-7.2%
6 Month	-48.9%	-48.9%
1 Year	-26.3%	-26.3%

More News

BioNexus Gene Lab Corp. Completes Chemrex Governance Restructuring; Appoints Matthew Barsing as Chairman

February 23, 2026

From BioNexus Gene Lab Corp.

Via GlobeNewswire

BioNexus Launches Regional Deployment of VitaGuard™ MRD Infrastructure; Positioned to Challenge Legacy Oncology Platforms Across ASEAN’s Multi-Billion Dollar Market

January 28, 2026

From BioNexus Gene Lab Corp.

Via GlobeNewswire

BioNexus Gene Lab Corp. Completes Strategic Investment in Fidelion Diagnostics; Secures 15% Equity Stake in Global AI-Oncology Platform and Exclusive Southeast Asian Rights for VitaGuard™

December 03, 2025

From BioNexus Gene Lab Corp.

Via GlobeNewswire

BioNexus Gene Lab Corp. (Nasdaq: BGLC) Secures $500 Million Equity Facility From ARC Group International to Support Expansion of Precision Diagnostics, CDMO Operations, and Therapeutic Commercialization

December 02, 2025

From BioNexus Gene Lab Corp.

Via GlobeNewswire

BioNexus Gene Lab Corp. (Nasdaq: BGLC) and Fidelion Diagnostics Execute Exclusive Southeast Asia License for VitaGuard™ MRD Platform as Part of Strategic Alliance with Tongshu Gene

December 01, 2025

From BioNexus Gene Lab Corp.

Via GlobeNewswire

12 Industrials Stocks Moving In Wednesday's After-Market Session ↗

November 12, 2025

Via Benzinga

BGLC Stock Tumbled Over 13% Today: Why Is VitaGuard Commercialization Agreement Drawing Investor Attention? ↗

November 12, 2025

Via Stocktwits

BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization

November 12, 2025

From BioNexus Gene Lab Corp.

Via GlobeNewswire

BioNexus Gene Lab Corp. Files $100 Million Shelf Registration and Establishes $20 Million At-the-Market Program to Advance Strategic Growth Opportunities

November 10, 2025

From BioNexus Gene Lab Corp.

Via GlobeNewswire

12 Industrials Stocks Moving In Monday's Pre-Market Session ↗

November 03, 2025

Via Benzinga

12 Industrials Stocks Moving In Monday's Pre-Market Session ↗

October 20, 2025

Via Benzinga

BioNexus Gene Lab Corp Signs Strategic Partnership Term Sheet with BirchBioMed Inc.

October 20, 2025

From BioNexus Gene Lab Corp.

Via GlobeNewswire

12 Industrials Stocks Moving In Friday's After-Market Session ↗

September 12, 2025

Via Benzinga

These stocks are moving in today's after hours session ↗

September 12, 2025

Via Chartmill

12 Industrials Stocks Moving In Friday's Intraday Session ↗

September 12, 2025

Via Benzinga

Which stocks are gapping on Friday? ↗

September 12, 2025

Via Chartmill

12 Industrials Stocks Moving In Friday's Pre-Market Session ↗

September 12, 2025

Via Benzinga

What's Driving the Market Sentiment Around BioNexus Gene Lab? ↗

August 19, 2025

Via Benzinga

12 Industrials Stocks Moving In Thursday's Pre-Market Session ↗

July 31, 2025

Via Benzinga

Which stocks are experiencing notable movement on Wednesday? ↗

July 30, 2025

Via Chartmill

12 Industrials Stocks Moving In Wednesday's Intraday Session ↗

July 30, 2025

Via Benzinga

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

July 30, 2025

Via Chartmill

Mag 7 Undercard: REPL, BGLC, TYGO, SGD – More Stocks Inside Heating Up Now!

July 30, 2025

Via AB Newswire

Frequently Asked Questions

Is BioNexus Gene Lab Corp - Common stock publicly traded?

Yes, BioNexus Gene Lab Corp - Common stock is publicly traded.

What exchange does BioNexus Gene Lab Corp - Common stock trade on?

BioNexus Gene Lab Corp - Common stock trades on the Nasdaq Stock Market

What is the ticker symbol for BioNexus Gene Lab Corp - Common stock?

The ticker symbol for BioNexus Gene Lab Corp - Common stock is BGLC on the Nasdaq Stock Market

What is the current price of BioNexus Gene Lab Corp - Common stock?

The current price of BioNexus Gene Lab Corp - Common stock is 2.320

When was BioNexus Gene Lab Corp - Common stock last traded?

The last trade of BioNexus Gene Lab Corp - Common stock was at 05/29/26 04:00 PM ET

What is the market capitalization of BioNexus Gene Lab Corp - Common stock?

The market capitalization of BioNexus Gene Lab Corp - Common stock is 4.17M

How many shares of BioNexus Gene Lab Corp - Common stock are outstanding?

BioNexus Gene Lab Corp - Common stock has 4M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.